GlassScriptPhysician profile
Stephen J Andrews
NPI 1255328845
$1,790.09
in general payments reported to CMS, 2019-2025
17 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $22.72 · 2021: $127 · 2022: $44.75 · 2023: $159 · 2024: $431 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $405.99 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $294.17 | 2023-2025 | |
| Clovis Oncology, INC. | $269.76 | 2019-2022 | |
| Genmab U.S., INC. | $207.12 | 2021-2025 | Tivdak |
| Abbvie INC. | $98.24 | 2024-2025 | |
| Glaxosmithkline, LLC. | $94.54 | 2019-2023 | Jemperli |
| Astrazeneca Pharmaceuticals LP | $81.88 | 2019-2025 | Lynparza |
| Tempus Ai, INC | $77.90 | 2024-2025 | Xt Cdx |
| Myriad Genetic Laboratories, INC. | $65.76 | 2024-2025 | Myrisk |
| Astellas Pharma US INC | $58.35 | 2024 | Veozah |
| Tesaro, INC. | $36.58 | 2019 | |
| Sumitomo Pharma America, INC. | $24.28 | 2024 | Myfembree |
| Amgen INC. | $22.01 | 2019 | |
| Kyowa Kirin, INC. | $21.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.35 | 2025 | Fruzaqla |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $10.39 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.